1. PapavramidouN, FeeE, Christopoulou‐AletraH. Jaundice in the hippocratic corpus. J Gastrointest Surg2007;11:1728. CrossRef

2. FrerichsFT. A Clinical Treatise on Diseases of the Liver, Translated by C. Murchison, 2 Vol.London: New Sydenham Society; 1860: 241.

3. ShawcrossDL, DaminkSWMO, ButterworthRF, et al.Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab Brain Dis2005;20:169. CrossRef

4. BajajJS, WadeJB, SanyalAJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology2009;50:2014. CrossRef

5. FerenciP, LockwoodA, MullenK, et al.Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th world congresses of gastroenterology, vienna, 1998. Hepatology2002;35:716. CrossRef

6. OrtizM, JacasC, CordobaJ. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. J Hepatol2005;42(Suppl 1):S45. CrossRef

7. RikkersL, JenkoP, RudmanD, et al.Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism. Gastroenterology1978;75:462.

8. BajajJS, CordobaJ, MullenKD, et al.Review article: the design of clinical trials in hepatic encephalopathy–an international society for hepatic encephalopathy and nitrogen metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther2011;33:739. CrossRef

9. BoyerTD, HaskalZJ, American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology2010;51:306. CrossRef

10. DasA, DhimanRK, SaraswatVA, et al.Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol2001;16:531. CrossRef

11. Maldonado‐GarzaHJ, Vazquez‐ElizondoG, Gaytan‐TorresJO, et al.Prevalence of minimal hepatic encephalopathy in cirrhotic patients. Ann Hepatol2011;10(Suppl 2):S40.

12. PoordadFF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther2007;25(Suppl 1):3. CrossRef

13. StepanovaM, MishraA, VenkatesanC, et al.In‐hospital mortality and economic burden associated with hepatic encephalopathy in the united states from 2005 to 2009. Clin Gastroenterol Hepatol2012;10:1034, e1. CrossRef

14. BajajJS, WadeJB, GibsonDP, et al.The multi‐dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol2011;106:184. CrossRef

15. RakoskiMO, McCammonRJ, PietteJD, et al.Burden of cirrhosis on older americans and their families: analysis of the health and retirement study. Hepatology2012;55:184. CrossRef

16. DesjardinsP, DuT, JiangW, et al.Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure: role of glutamine redefined. Neurochem Int2012;60:690. CrossRef

17. HaussingerD, SchliessF. Pathogenetic mechanisms of hepatic encephalopathy. Gut2008;57:1156. CrossRef

18. WrightG, NoiretL, Olde DaminkSW, et al.Interorgan ammonia metabolism in liver failure: the basis of current and future therapies. Liver Int2010;31:163. CrossRef

19. HaussingerD. Hepatocyte heterogeneity in glutamine and ammonia metabolism and the role of an intercellular glutamine cycle during ureogenesis in perfused rat liver. Eur J Biochem1983;133:269. CrossRef

20. YtreboLM, SenS, RoseC, et al.Interorgan ammonia, glutamate, and glutamine trafficking in pigs with acute liver failure. Am J Physiol Gastrointest Liver Physiol2006;291:G373. CrossRef

21. BajajJS, HylemonPB, RidlonJM, et al.The colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol2012;303:G675. CrossRef

22. RudmanD, DiFulcoTJ, GalambosJT, et al.Maximal rates of excretion and synthesis of urea in normal and cirrhotic subjects. J Clin Invest1973;52:2241. CrossRef

23. KaiserS, GerokW, HaussingerD. Ammonia and glutamine metabolism in human liver slices: new aspects on the pathogenesis of hyperammonaemia in chronic liver disease. Eur J Clin Invest1988;18:535. CrossRef

24. DebatinJF, ZahnerB, MeyenbergerC, et al.Azygos blood flow: phase contrast quantitation in volunteers and patients with portal hypertension pre‐ and postintrahepatic shunt placement. Hepatology1996;24:1109. CrossRef

25. WalserEM, HarrisVM, HarmanJT, et al.Quantification of intrahepatic portosystemic shunting after placement of a transjugular intrahepatic portosystemic shunt. J Vasc Interv Radiol1996;7:263. CrossRef

26. GandaOP, RudermanNB. Muscle nitrogen metabolism in chronic hepatic insufficiency. Metabolism1976;25:427. CrossRef

27. OwenEE, TyorMP, FlanaganJF, et al.The kidney as a source of blood ammonia in patients with liver disease: the effect of acetazolamide. J Clin Invest1960;39:288. CrossRef

28. Olde DaminkSW, JalanR, DeutzNE, et al.The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. Hepatology2003;37:1277. CrossRef

29. JalanR, KapoorD. Reversal of diuretic‐induced hepatic encephalopathy with infusion of albumin but not colloid. Clin Sci (Lond)2004;106:467. CrossRef

30. TrycAB, GoldbeckerA, BerdingG, et al.Cirrhosis‐related parkinsonism: prevalence, mechanisms and response to treatments. J Hepatol2013;58:698. CrossRef

31. PujolA, PujolJ, GrausF, et al.Hyperintense globus pallidus on T1‐weighted MRI in cirrhotic patients is associated with severity of liver failure. Neurology1993;43:65. CrossRef

32. Pomier‐LayrarguesG, SpahrL, ButterworthRF. Increased manganese concentrations in pallidum of cirrhotic patients. Lancet1995;345:735. CrossRef

33. RoseC, ButterworthRF, ZayedJ, et al.Manganese deposition in basal ganglia structures results from both portal‐systemic shunting and liver dysfunction. Gastroenterology1999;117:640. CrossRef

34. Rivera‐ManciaS, RiosC, MontesS. Manganese and ammonia interactions in the brain of cirrhotic rats: effects on brain ammonia metabolism. Neurochem Res2012;37:1074. CrossRef

35. IversenP, SorensenM, BakLK, et al.Low cerebral oxygen consumption and blood flow in patients with cirrhosis and an acute episode of hepatic encephalopathy. Gastroenterology2009;136:863. CrossRef

36. DamG, KeidingS, MunkOL, et al.Hepatic encephalopathy is associated with decreased cerebral oxygen metabolism and blood flow, not increased ammonia uptake. Hepatology2013;57:258. CrossRef

37. LockwoodAH, YapEW, WongWH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab1991;11:337. CrossRef

38. ZhangLJ, YangG, YinJ, et al.Abnormal default‐mode network activation in cirrhotic patients: a functional magnetic resonance imaging study. Acta Radiol2007;48:781. CrossRef

39. KeidingS, PaveseN. Brain metabolism in patients with hepatic encephalopathy studied by PET and MR. Arch Biochem Biophys2013;536:131. CrossRef

40. ZafirisO, KircheisG, RoodHA, et al.Neural mechanism underlying impaired visual judgement in the dysmetabolic brain: an fMRI study. Neuroimage2004;22:541. CrossRef

41. WeissenbornK, AhlB, Fischer‐WaselsD, et al.Correlations between magnetic resonance spectroscopy alterations and cerebral ammonia and glucose metabolism in cirrhotic patients with and without hepatic encephalopathy. Gut2007;56:1736. CrossRef

42. HindfeltB, PlumF, DuffyTE. Effect of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts. J Clin Invest1977;59:386. CrossRef

43. YaoH, SadoshimaS, FujiiK, et al.Cerebrospinal fluid lactate in patients with hepatic encephalopathy. Eur Neurol1987;27:182. CrossRef

44. MansAM, DeJosephMR, HawkinsRA. Metabolic abnormalities and grade of encephalopathy in acute hepatic failure. J Neurochem1994;63:1829. CrossRef

45. BosmanDK, DeutzNE, De GraafAA, et al.Changes in brain metabolism during hyperammonemia and acute liver failure: results of a comparative 1H‐NMR spectroscopy and biochemical investigation. Hepatology1990;12:281. CrossRef

46. LavoieJ, GiguereJF, LayrarguesGP, et al.Amino acid changes in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. J Neurochem1987;49:692. CrossRef

47. HermenegildoC, MonfortP, FelipoV. Activation of N‐methyl‐D‐aspartate receptors in rat brain in vivo following acute ammonia intoxication: characterization by in vivo brain microdialysis. Hepatology2000;31:709. CrossRef

48. PetersonC, GiguereJF, CotmanCW, et al.Selective loss of N‐methyl‐D‐aspartate‐sensitive L‐[3H]glutamate binding sites in rat brain following portacaval anastomosis. J Neurochem1990;55:386. CrossRef

49. MarcaidaG, MinanaMD, BurgalM, et al.Ammonia prevents activation of NMDA receptors by glutamate in rat cerebellar neuronal cultures. Eur J Neurosci1995;7:2389. CrossRef

50. ElMliliN, BoixJ, AhabrachH, et al.Chronic hyperammonemia induces tonic activation of NMDA receptors in cerebellum. J Neurochem2010;112:1005. CrossRef

51. Palomero‐GallagherN, BidmonHJ, CremerM, et al.Neurotransmitter receptor imbalances in motor cortex and basal ganglia in hepatic encephalopathy. Cell Physiol Biochem2009;24:291. CrossRef

52. ButterworthRF, GiguereJF. Cerebral aminoacids in portal‐systemic encephalopathy: lack of evidence for altered gamma‐aminobutyric acid (GABA) function. Metab Brain Dis1986;1:221. CrossRef

53. RoyS, Pomier‐LayrarguesG, ButterworthRF, et al.Hepatic encephalopathy in cirrhotic and portacaval shunted dogs: lack of changes in brain GABA uptake, brain GABA levels, brain glutamic acid decarboxylase activity and brain postsynaptic GABA receptors. Hepatology1988;8:845. CrossRef

54. MansAM, KukulkaKM, McAvoyKJ, et al.Regional distribution and kinetics of three sites on the GABAA receptor: lack of effect of portacaval shunting. J Cereb Blood Flow Metab1992;12:334. CrossRef

55. Pomier‐LayrarguesG, GiguereJF, LavoieJ, et al.Flumazenil in cirrhotic patients in hepatic coma: a randomized double‐blind placebo‐controlled crossover trial. Hepatology1994;19:32.

56. GyrK, MeierR, HausslerJ, et al.Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. Gut1996;39:319. CrossRef

57. MullenKD, SzauterKM, Kaminsky‐RussK. “Endogenous” benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet1990;336:81. CrossRef

58. CasellasP, GaliegueS, BasileAS. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int2002;40:475. CrossRef

59. AhbouchaS, LayrarguesGP, MamerO, et al.Increased brain concentrations of a neuroinhibitory steroid in human hepatic encephalopathy. Ann Neurol2005;58:169. CrossRef

60. ShiraishiT, BlackKL, IkezakiK, et al.Peripheral benzodiazepine induces morphological changes and proliferation of mitochondria in glioma cells. J Neurosci Res1991;30:463. CrossRef

61. SkowronskaM, AlbrechtJ. Oxidative and nitrosative stress in ammonia neurotoxicity. Neurochem Int2013;62:731. CrossRef

62. RothsteinJD, McKhannG, GuarneriP, et al.Cerebrospinal fluid content of diazepam binding inhibitor in chronic hepatic encephalopathy. Ann Neurol1989;26:57. CrossRef

63. ButterworthRF, TononMC, DesyL, et al.Increased brain content of the endogenous benzodiazepine receptor ligand, octadecaneuropeptide (ODN), following portacaval anastomosis in the rat. Peptides1991;12:119. CrossRef

64. YoungSN, LalS, SourkesTL, et al.Relationships between tryptophan in serum and CSF, and 5‐hydroxyindoleacetic acid in CSF of man: effect of cirrhosis of liver and probenecid administration. J Neurol Neurosurg Psychiatry1975;38:322. CrossRef

65. BergeronM, ReaderTA, LayrarguesGP, et al.Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Neurochem Res1989;14:853. CrossRef

66. MousseauDD, BakerGB, ButterworthRF. Increased density of catalytic sites and expression of brain monoamine oxidase A in humans with hepatic encephalopathy. J Neurochem1997;68:1200. CrossRef

67. Lozeva‐ThomasV. Serotonin brain circuits with a focus on hepatic encephalopathy. Metab Brain Dis2004;19:413. CrossRef

68. MoreauAW, AmarM, Le RouxN, et al.Serotoninergic fine‐tuning of the excitation‐inhibition balance in rat visual cortical networks. Cereb Cortex2010;20:456. CrossRef

69. LozevaV, MontgomeryJA, TuomistoL, et al.Increased brain serotonin turnover correlates with the degree of shunting and hyperammonemia in rats following variable portal vein stenosis. J Hepatol2004;40:742. CrossRef

70. BeaubernardC, DelormeML, OpolonP, et al.Effect of the oral administration of branched chain amino acids on hepatic encephalopathy in the rat. Hepatology1984;4:288. CrossRef

71. SergeevaOA, SchulzD, DoreuleeN, et al.Deficits in cortico‐striatal synaptic plasticity and behavioral habituation in rats with portacaval anastomosis. Neuroscience2005;134:1091. CrossRef

72. SuzukiO, IshiiK, NagataH, et al.Role of plasma histamine in liver injury–clinical and experimental investigations. Gastroenterol Jpn1979;14:336.

73. BorgJ, WarterJM, SchliengerJL, et al.Neurotransmitter modifications in human cerebrospinal fluid and serum during hepatic encephalopathy. J Neurol Sci1982;57:343. CrossRef

74. LozevaV, TuomistoL, TarhanenJ, et al.Increased concentrations of histamine and its metabolite, tele‐methylhistamine and down‐regulation of histamine H3 receptor sites in autopsied brain tissue from cirrhotic patients who died in hepatic coma. J Hepatol2003;39:522. CrossRef

75. SpahrL, CoeytauxA, GiostraE, et al.Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Am J Gastroenterol2007;102:744. CrossRef

76. CuilleretG, Pomier‐LayrarguesG, PonsF, et al.Changes in brain catecholamine levels in human cirrhotic hepatic encephalopathy. Gut1980;21:565. CrossRef

77. KnellAJ, DavidsonAR, WilliamsR, et al.Dopamine and serotonin metabolism in hepatic encephalopathy. Br Med J1974;1:549. CrossRef

78. AlbrechtJ, JonesEA. Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome. J Neurol Sci1999;170:138. CrossRef

79. Palomero‐GallagherN, ZillesK. Neurotransmitter receptor alterations in hepatic encephalopathy: a review. Arch Biochem Biophys2013;536:109. CrossRef

80. LaidlawJ, ReadAE, SherlockS. Morphine tolerance in hepatic cirrhosis. Gastroenterology1961;40:389.

81. KamelL, SalehA, MorsyA, et al.Plasma met‐enkephalin, beta‐endorphin and leu‐enkephalin levels in human hepatic encephalopathy. East Mediterr Health J2007;13:257.

82. YurdaydinC, KaraveliogluD, OnaranO, et al.Opioid receptor ligands in human hepatic encephalopathy. J Hepatol1998;29:796. CrossRef

83. ShawcrossDL, DaviesNA, WilliamsR, et al.Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol2004;40:247. CrossRef

84. MerliM, LucidiC, PentassuglioI, et al.Increased risk of cognitive impairment in cirrhotic patients with bacterial infections. J Hepatol2013;59:243. CrossRef

85. LesesneHR, BozymskiEM, FallonHJ. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology1978;74:169.

86. WeiserKT, SuriawinataAA, van LeeuwenDJ. A 56‐year‐old man with sudden onset of portosystemic encephalopathy years after severe electrocution trauma. Semin Liver Dis2008;28:328. CrossRef

87. Al IniziS, RobertsonIG. Acute hepatic encephalopathy with acute pancreatitis in pregnancy. J Obstet Gynaecol2006;26:257. CrossRef

88. HuBL, WangHY, YangGY. Association of helicobacter pylori infection with hepatic encephalopathy risk: a systematic review. Clin Res Hepatol Gastroenterol2013;37:619. CrossRef

89. HungTH, LayCJ, ChangCM, et al.The effect of infections on the mortality of cirrhotic patients with hepatic encephalopathy. Epidemiol Infect2013;141:2671. CrossRef

90. BleiAT. Infection, inflammation and hepatic encephalopathy, synergism redefined. J Hepatol2004;40:327. CrossRef

91. NagakiM, IwaiH, NaikiT, et al.High levels of serum interleukin‐10 and tumor necrosis factor‐alpha are associated with fatality in fulminant hepatitis. J Infect Dis2000;182:1103. CrossRef

92. GenescaJ, GonzalezA, SeguraR, et al.Interleukin‐6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol1999;94:169. CrossRef

93. LicinioJ, WongML. Pathways and mechanisms for cytokine signaling of the central nervous system. J Clin Invest1997;100:2941. CrossRef

94. TanKH, HarringtonS, PurcellWM, et al.Peroxynitrite mediates nitric oxide‐induced blood‐brain barrier damage. Neurochem Res2004;29:579. CrossRef

95. WrightG, ShawcrossD, Olde DaminkSW, et al.Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. Metab Brain Dis2007;22:375. CrossRef

96. YoungRR, ShahaniBT. Asterixis: one type of negative myoclonus. Adv Neurol1986;43:137.

97. YamamotoY, NishiyamaY, KatsuraKI, et al.Hepatic encephalopathy with reversible focal neurologic signs resembling acute stroke: case report. J Stroke Cerebrovasc Dis2011;20:377. CrossRef

98. AtchisonJW, PellegrinoM, HerbersP, et al.Hepatic encephalopathy mimicking stroke. A case report. Am J Phys Med Rehabil1992;71:114. CrossRef

99. TanakaH, UedaH, KidaY, et al.Hepatic encephalopathy with status epileptics: a case report. World J Gastroenterol2006;12:1793.

100. EleftheriadisN, FourlaE, EleftheriadisD, et al.Status epilepticus as a manifestation of hepatic encephalopathy. Acta Neurol Scand2003;107:142. CrossRef

101. ZhangLJ, QiR, ZhongJ, et al.The effect of hepatic encephalopathy, hepatic failure, and portosystemic shunt on brain volume of cirrhotic patients: a voxel‐based morphometry study. PLoS ONE2012;7:e42824. CrossRef

102. SobukawaE, SakimuraK, HoshinoS, et al.Hepatic myelopathy: an unusual neurological complication of advanced hepatic disease. Intern Med1994;33:718. CrossRef

103. BernalW, HallC, KarvellasCJ, et al.Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology2007;46:1844. CrossRef

104. ClemmesenJO, LarsenFS, KondrupJ, et al.Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology1999;29:648. CrossRef

105. BajajJS. Review article: the modern management of hepatic encephalopathy. Aliment Pharmacol Ther2010;31:537. CrossRef

106. OngJP, AggarwalA, KriegerD, et al.Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med2003;114:188. CrossRef

107. WangV, SaabS. Ammonia levels and the severity of hepatic encephalopathy. Am J Med2003;114:237. CrossRef

108. HassaneinT, BleiAT, PerryW, et al.Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. Am J Gastroenterol2009;104:1392. CrossRef

109. BassNM, MullenKD, SanyalA, et al.Rifaximin treatment in hepatic encephalopathy. N Engl J Med2010;362:1071. CrossRef

110. OrtizM, CordobaJ, DovalE, et al.Development of a clinical hepatic encephalopathy staging scale. Aliment Pharmacol Ther2007;26:859. CrossRef

111. RockeyDC, VierlingJM, MantryP, et al.Randomized, double‐blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology2014;59:1073. CrossRef

112. SalamM, MatherlyS, FarooqIS, et al.Modified‐orientation log to assess hepatic encephalopathy. Aliment Pharmacol Ther2012;35:913. CrossRef

113. KappusMR, BajajJS. Covert hepatic encephalopathy: not as minimal as you might think. Clin Gastroenterol Hepatol2012;10:1208. CrossRef

114. BajajJS, ThackerLR, HeumanDM, et al.The stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology2013;58:1122. CrossRef

115. CordobaJ, Lopez‐HellinJ, PlanasM, et al.Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol2004;41:38. CrossRef

116. MullenKD, DasarathyS. Protein restriction in hepatic encephalopathy: necessary evil or illogical dogma?J Hepatol2004;41:147. CrossRef

117. AmodioP, BemeurC, ButterworthR, et al.The nutritional management of hepatic encephalopathy in patients with cirrhosis: Ishen consensus. Hepatology2013;58:325. CrossRef

118. TomiyaT, InoueY, YanaseM, et al.Leucine stimulates the secretion of hepatocyte growth factor by hepatic stellate cells. Biochem Biophys Res Commun2002;297:1108. CrossRef

119. BemeurC, DesjardinsP, ButterworthRF. Role of nutrition in the management of hepatic encephalopathy in end‐stage liver failure. J Nutr Metab2010;2010:489823. CrossRef

120. ErikssonLS, PerssonA, WahrenJ. Branched‐chain amino acids in the treatment of chronic hepatic encephalopathy. Gut1982;23:801. CrossRef

121. WahrenJ, DenisJ, DesurmontP, et al.Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study. Hepatology1983;3:475. CrossRef

122. EgbertsEH, SchomerusH, HamsterW, et al.Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double‐blind placebo‐controlled crossover study. Gastroenterology1985;88:887.

123. PlauthM, EgbertsEH, HamsterW, et al.Long‐term treatment of latent portosystemic encephalopathy with branched‐chain amino acids. A double‐blind placebo‐controlled crossover study. J Hepatol1993;17:308. CrossRef

124. MarchesiniG, DioguardiFS, BianchiGP, et al.Long‐term oral branched‐chain amino acid treatment in chronic hepatic encephalopathy. A randomized double‐blind casein‐controlled trial. The italian multicenter study group. J Hepatol1990;11:92. CrossRef

125. GreenbergerNJ, CarleyJ, SchenkerS, et al.Effect of vegetable and animal protein diets in chronic hepatic encephalopathy. Am J Dig Dis1977;22:845. CrossRef

126. KeshavarzianA, MeekJ, SuttonC, et al.Dietary protein supplementation from vegetable sources in the management of chronic portal systemic encephalopathy. Am J Gastroenterol1984;79:945.

127. BianchiGP, MarchesiniG, FabbriA, et al.Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross‐over comparison. J Intern Med1993;233:385. CrossRef

128. SimmonsF, GoldsteinH, BoyleJD. A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology1970;59:827.

129. ClausenMR, MortensenPB. Lactulose, disaccharides and colonic flora. Clinical consequences. Drugs1997;53:930. CrossRef

130. Als‐NielsenB, GluudLL, GluudC. Non‐absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ2004;328:1046. CrossRef

131. SharmaP, SharmaBC, SarinSK. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy. Eur J Gastroenterol Hepatol2010;22:526. CrossRef

132. JalanR. Rifaximin in hepatic encephalopathy: more than just a non‐absorbable antibiotic?J Hepatol2010;53:580. CrossRef

133. RiggioO, MannaioniG, RidolaL, et al.Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: a study on the pathophysiology of hepatic encephalopathy. Am J Gastroenterol2010;105:1374. CrossRef

134. StraussE, TramoteR, SilvaEP, et al.Double‐blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology1992;39:542.

135. MorganMH, ReadAE, SpellerDC. Treatment of hepatic encephalopathy with metronidazole. Gut1982;23:1. CrossRef

136. LoftS, SonneJ, DossingM, et al.Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol1987;22:117. CrossRef

137. TaraoK, IkedaT, HayashiK, et al.Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut1990;31:702. CrossRef

138. TestaR, EftimiadiC, SukkarGS, et al.A non‐absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res1985;11:387.

139. JiangZD, DuPontHL. Rifaximin: in vitro and in vivo antibacterial activity–a review. Chemotherapy2005;51(Suppl 1):67. CrossRef

140. PatidarKR, BajajJS. Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis2013;28:307. CrossRef

141. HuchzermeyerH, SchumannC. Lactulose–a multifaceted substance. Z Gastroenterol1997;35:945.

142. AgrawalA, SharmaBC, SharmaP, et al.Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open‐label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol2012;107:1043. CrossRef

143. HolteK, KragA, GluudLL. Systematic review and meta‐analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol Res2012;42:1008. CrossRef

144. McGeeRG, BakensA, WileyK, et al.Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev2011;(11):CD008716.

145. Als‐NielsenB, KjaergardLL, GluudC. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy. Cochrane Database Syst Rev2001;(4):CD002798.

146. CorenblumB, ShafferEA. Hyperprolactinemia in hepatic encephalopathy may result from impaired central dopaminergic neurotransmission. Horm Metab Res1989;21:675. CrossRef

147. FischerJE, FunovicsFJ, FalcaoHA, et al.L‐dopa in hepatic coma. Ann Surg1976;183:386. CrossRef

148. UribeM, Garcia‐RamosG, RamosM, et al.Standard and higher doses of bromocriptine for severe chronic portal‐systemic encephalopathy. Am J Gastroenterol1983;78:517.

149. KircheisG, WettsteinM, DahlS, et al.Clinical efficacy of L‐ornithine‐L‐aspartate in the management of hepatic encephalopathy. Metab Brain Dis2002;17:453. CrossRef

150. JiangQ, JiangX, ZhengM, et al.L‐ornithine‐L‐aspartate in the management of hepatic encephalopathy: a meta‐analysis. J Gastroenterol Hepatol2009;24:9. CrossRef

151. BaiM, YangZ, QiX, et al.L‐ornithine‐L‐aspartate for hepatic encephalopathy in patients with cirrhosis: a meta‐analysis of randomized controlled trials. J Gastroenterol Hepatol2013;28:783. CrossRef

152. MendenhallCL, RousterS, MarshallL, et al.A new therapy for portal systemic encephalopathy. Am J Gastroenterol1986;81:540.

153. HeemannU, TreichelU, LoockJ, et al.Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology2002;36:949. CrossRef

154. HassaneinTI, ToftengF, BrownRSJr, et al.Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology2007;46:1853. CrossRef

155. BanaresR, NevensF, LarsenFS, et al.Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute‐on‐chronic liver failure: the RELIEF trial. Hepatology2013;57:1153. CrossRef

156. DhimanRK, KurmiR, ThumburuKK, et al.Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci2010;55:2381. CrossRef

157. BustamanteJ, RimolaA, VenturaPJ, et al.Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol1999;30:890. CrossRef

158. CordobaJ, SanpedroF, AlonsoJ, et al.1H magnetic resonance in the study of hepatic encephalopathy in humans. Metab Brain Dis2002;17:415. CrossRef

159. SenzoloM, PizzolatoG, FerronatoC, et al.Long‐term evaluation of cognitive function and cerebral metabolism in liver transplanted patients. Transplant Proc2009;41:1295. CrossRef

160. MattarozziK, CretellaL, GuarinoM, et al.Minimal hepatic encephalopathy: follow‐up 10 years after successful liver transplantation. Transplantation2012;93:639.

161. MattarozziK, StracciariA, VignatelliL, et al.Minimal hepatic encephalopathy: longitudinal effects of liver transplantation. Arch Neurol2004;61:242. CrossRef

162. SotilEU, GottsteinJ, AyalaE, et al.Impact of preoperative overt hepatic encephalopathy on neurocognitive function after liver transplantation. Liver Transpl2009;15:184. CrossRef

163. PujolA, GrausF, RimolaA, et al.Predictive factors of in‐hospital CNS complications following liver transplantation. Neurology1994;44:1226. CrossRef

164. BlancoR, De GirolamiU, JenkinsRL, et al.Neuropathology of liver transplantation. Clin Neuropathol1995;14:109.

165. BajajJS, SaeianK, HafeezullahM, et al.Patients with minimal hepatic encephalopathy have poor insight into their driving skills. Clin Gastroenterol Hepatol2008;6:1135, quiz 1065. CrossRef

166. BajajJS, ThackerLR, HeumanDM, et al.Driving simulation can improve insight into impaired driving skills in cirrhosis. Dig Dis Sci2012;57:554. CrossRef

167. SharmaP, SharmaBC, AgrawalA, et al.Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol2012;27:1329. CrossRef

168. MittalVV, SharmaBC, SharmaP, et al.A randomized controlled trial comparing lactulose, probiotics, and L‐ornithine L‐aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol2011;23:725. CrossRef

169. SharmaP, SharmaBC, PuriV, et al.An open‐label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol2008;20:506. CrossRef

170. PrasadS, DhimanRK, DusejaA, et al.Lactulose improves cognitive functions and health‐related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology2007;45:549. CrossRef

171. BajajJS, HeumanDM, WadeJB, et al.Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology2011;140:478, e1. CrossRef

172. SidhuSS, GoyalO, MishraBP, et al.Rifaximin improves psychometric performance and health‐related quality of life in patients with minimal hepatic encephalopathy (the RIME trial). Am J Gastroenterol2011;106:307. CrossRef

173. BajajJS, HeumanDM, SanyalAJ, et al.Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS ONE2013;8:e60042. CrossRef

174. BajajJS, SaeianK, ChristensenKM, et al.Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol2008;103:1707. CrossRef

175. LiuQ, DuanZP, HaDK, et al.Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology2004;39:1441. CrossRef

176. SajiS, KumarS, ThomasV. A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Trop Gastroenterol2011;32:128.

177. DubinskyRM, SteinAC. Minimal hepatic encephalopathy and driving. Hepatology2009;50:1007. CrossRef

178. KircheisG, KnocheA, HilgerN, et al.Hepatic encephalopathy and fitness to drive. Gastroenterology2009;137:1706, e1‐9. CrossRef

179. BajajJS, HafeezullahM, HoffmannRG, et al.Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol2007;102:1903. CrossRef

180. BajajJS, HafeezullahM, HoffmannRG, et al.Navigation skill impairment: another dimension of the driving difficulties in minimal hepatic encephalopathy. Hepatology2008;47:596. CrossRef

181. BajajJS, SaeianK, SchubertCM, et al.Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology2009;50:1175. CrossRef

182. GadYZ, ZaherAA, MoussaNH, et al.Screening for minimal hepatic encephalopathy in asymptomatic drivers with liver cirrhosis. Arab J Gastroenterol2011;12:58. CrossRef

183. BajajJS, AnanthakrishnanAN, McGinleyEL, et al.Deleterious effect of cirrhosis on outcomes after motor vehicle crashes using the nationwide inpatient sample. Am J Gastroenterol2008;103:1674. CrossRef

184. FluckigerM. Vorkommen von trommelschagel formigen fingerendphalangen ohne chronische veranderungen and der lungen oder am herzen. Wien Klin Wochenschr1884;34:1457.

185. SnellA. The effects of chronic disease of the liver on the composition and physicochemical properties of blood: changes in the serum proteins; reduction in the oxygen saturation of the arterial blood. Ann Intern Med1935;9:690. CrossRef

186. BerthelotP, WalkerJG, SherlockS, et al.Arterial changes in the lungs in cirrhosis of the liver–lung spider nevi. N Engl J Med1966;274:291. CrossRef

187. KennedyTC, KnudsonRJ. Exercise‐aggravated hypoxemia and orthodeoxia in cirrhosis. Chest1977;72:305. CrossRef

188. Rodriguez‐RoisinR, KrowkaMJ, HerveP, et al.Pulmonary‐hepatic vascular disorders (PHD). Eur Respir J2004;24:861. CrossRef

189. PalmaDT, FallonMB. The hepatopulmonary syndrome. J Hepatol2006;45:617. CrossRef

190. ArguedasMR, SinghH, FaulkDK, et al.Utility of pulse oximetry screening for hepatopulmonary syndrome. Clin Gastroenterol Hepatol2007;5:749. CrossRef

191. AbramsGA, NandaNC, DubovskyEV, et al.Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology1998;114:305. CrossRef

192. MartinezG, BarberaJA, NavasaM, et al.Hepatopulmonary syndrome associated with cardiorespiratory disease. J Hepatol1999;30:882. CrossRef

193. StollerJK, LangePA, WestveerMK, et al.Prevalence and reversibility of the hepatopulmonary syndrome after liver transplantation. The cleveland clinic experience. West J Med1995;163:133.

194. MartinezGP, BarberaJA, VisaJ, et al.Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol2001;34:651. CrossRef

195. SchenkP, FuhrmannV, MadlC, et al.Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut2002;51:853. CrossRef

196. KrowkaMJ, TajikAJ, DicksonER, et al.Intrapulmonary vascular dilatations (IPVD) in liver transplant candidates. Screening by two‐dimensional contrast‐enhanced echocardiography. Chest1990;97:1165. CrossRef

197. FallonMB, KrowkaMJ, BrownRS, et al.Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology2008;135:1168. CrossRef

198. SchenkP, Schoniger‐HekeleM, FuhrmannV, et al.Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology2003;125:1042. CrossRef

199. DeibertP, AllgaierHP, LoeschS, et al.Hepatopulmonary syndrome in patients with chronic liver disease: role of pulse oximetry. BMC Gastroenterol2006;6:15. CrossRef

200. TeuberG, TeupeC, DietrichCF, et al.Pulmonary dysfunction in non‐cirrhotic patients with chronic viral hepatitis. Eur J Intern Med2002;13:311. CrossRef

201. KaymakogluS, KahramanT, KudatH, et al.Hepatopulmonary syndrome in noncirrhotic portal hypertensive patients. Dig Dis Sci2003;48:556. CrossRef

202. YapFK, AwMM, QuekSC, et al.Hepatopulmonary syndrome: a rare complication of chronic liver disease in children. Ann Acad Med Singapore1999;28:290.

203. DeBK, SenS, BiswasPK, et al.Occurrence of hepatopulmonary syndrome in budd‐chiari syndrome and the role of venous decompression. Gastroenterology2002;122:897. CrossRef

204. RegevA, YeshurunM, RodriguezM, et al.Transient hepatopulmonary syndrome in a patient with acute hepatitis A. J Viral Hepat2001;8:83. CrossRef

205. WilliamsA, TrewbyP, WilliamsR, et al.Structural alterations to the pulmonary circulation in fulminant hepatic failure. Thorax1979;34:447. CrossRef

206. FuhrmannV, MadlC, MuellerC, et al.Hepatopulmonary syndrome in patients with hypoxic hepatitis. Gastroenterology2006;131:69. CrossRef

207. KrowkaMJ, WisemanGA, BurnettOL, et al.Hepatopulmonary syndrome: a prospective study of relationships between severity of liver disease, PaO(2) response to 100% oxygen, and brain uptake after (99m)tc MAA lung scanning. Chest2000;118:615. CrossRef

208. DavisHH, SchwartzD, LefrakS, et al.Alveolar‐capillary oxygen disequilibrium in hepatic cirrhosis. Chest1978;73:507. CrossRef

209. HalesMR. Multiple small arteriovenous fistulae of the lungs. Am J Pathol1956;32:927.

210. CalabresiP, AbelmannWH. Porto‐caval and porto‐pulmonary anastomoses in laennec's cirrhosis and in heart failure. J Clin Invest1957;36:1257. CrossRef

211. StanleyNN, WilliamsAJ, DewarCA, et al.Hypoxia and hydrothoraces in a case of liver cirrhosis: correlation of physiological, radiographic, scintigraphic, and pathological findings. Thorax1977;32:457. CrossRef

212. AllerR, MoyaJL, MoreiraV, et al.Diagnosis of hepatopulmonary syndrome with contrast transesophageal echocardiography: advantages over contrast transthoracic echocardiography. Dig Dis Sci1999;44:1243. CrossRef

213. HouraniJM, BellamyPE, TashkinDP, et al.Pulmonary dysfunction in advanced liver disease: frequent occurrence of an abnormal diffusing capacity. Am J Med1991;90:693. CrossRef

214. KrowkaMJ, DicksonER, WiesnerRH, et al.A prospective study of pulmonary function and gas exchange following liver transplantation. Chest1992;102:1161. CrossRef

215. KrowkaMJ, DicksonER, CorteseDA. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest1993;104:515. CrossRef

216. KrowkaMJ, CorteseDA. Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation. Hepatology1990;11:138. CrossRef

217. KatsutaY, HonmaH, ZhangXJ, et al.Pulmonary blood transit time and impaired arterial oxygenation in patients with chronic liver disease. J Gastroenterol2005;40:57. CrossRef

218. MelotC, NaeijeR, DechampsP, et al.Pulmonary and extrapulmonary contributors to hypoxemia in liver cirrhosis. Am Rev Respir Dis1989;139:632. CrossRef

219. Rodriguez‐RoisinR, RocaJ, AgustiAG, et al.Gas exchange and pulmonary vascular reactivity in patients with liver cirrhosis. Am Rev Respir Dis1987;135:1085.

220. Rodriguez‐RoisinR, BarberaJA. Hepatopulmonary syndrome: is NO the right answer?Gastroenterology1997;113:682. CrossRef

221. SchraufnagelDE, KayJM. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med1996;17:1. CrossRef

222. AgustiAG, RocaJ, Rodriguez‐RoisinR. Mechanisms of gas exchange impairment in patients with liver cirrhosis. Clin Chest Med1996;17:49. CrossRef

223. SrivastavaD, PremingerT, LockJE, et al.Hepatic venous blood and the development of pulmonary arteriovenous malformations in congenital heart disease. Circulation1995;92:1217. CrossRef

224. ChangSW, OharaN. Pulmonary circulatory dysfunction in rats with biliary cirrhosis. An animal model of the hepatopulmonary syndrome. Am Rev Respir Dis1992;145:798. CrossRef

225. FallonMB, AbramsGA, McGrathJW, et al.Common bile duct ligation in the rat: a model of intrapulmonary vasodilatation and hepatopulmonary syndrome. Am J Physiol1997;272:G779.

226. GraceJA, AngusPW. Hepatopulmonary syndrome: update on recent advances in pathophysiology, investigation and treatment. J Gastroenterol Hepatol2013;28:213. CrossRef

227. RollaG. Is nitric oxide the ultimate mediator in hepatopulmonary syndrome?J Hepatol2003;38:668. CrossRef

228. FallonMB. Mechanisms of pulmonary vascular complications of liver disease: hepatopulmonary syndrome. J Clin Gastroenterol2005;39(4 Suppl 2):S138. CrossRef

229. RollaG, BuccaC, BrussinoL. Methylene blue in the hepatopulmonary syndrome. N Engl J Med1994;331:1098. CrossRef

230. SchenkP, MadlC, Rezaie‐MajdS, et al.Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med2000;133:701. CrossRef

231. MiyamotoA, KatsutaY, ZhangXJ, et al.Effect of chronic methylene blue administration on hypoxemia in rats with common bile duct ligation. Hepatol Res2010;40:622. CrossRef

232. BrussinoL, BuccaC, MorelloM, et al.Effect on dyspnoea and hypoxaemia of inhaled N(G)‐nitro‐L‐arginine methyl ester in hepatopulmonary syndrome. Lancet2003;362:43. CrossRef

233. ZhangXJ, KatsutaY, AkimotoT, et al.Intrapulmonary vascular dilatation and nitric oxide in hypoxemic rats with chronic bile duct ligation. J Hepatol2003;39:724. CrossRef

234. GomezFP, BarberaJA, RocaJ, et al.Effects of nebulized N(G)‐nitro‐L‐arginine methyl ester in patients with hepatopulmonary syndrome. Hepatology2006;43:1084. CrossRef

235. LingY, ZhangJ, LuoB, et al.The role of endothelin‐1 and the endothelin B receptor in the pathogenesis of hepatopulmonary syndrome in the rat. Hepatology2004;39:1593. CrossRef

236. RabillerA, NunesH, LebrecD, et al.Prevention of gram‐negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med2002;166:514. CrossRef

237. NunesH, LebrecD, MazmanianM, et al.Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med2001;164:879. CrossRef

238. ZhangJ, LingY, LuoB, et al.Analysis of pulmonary heme oxygenase‐1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. Gastroenterology2003;125:1441. CrossRef

239. SztrymfB, LibertJM, MougeotC, et al.Cirrhotic rats with bacterial translocation have higher incidence and severity of hepatopulmonary syndrome. J Gastroenterol Hepatol2005;20:1538. CrossRef

240. GuptaS, FaughnanME, LillyL, et al.Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial. Clin Gastroenterol Hepatol2010;8:1095. CrossRef

241. LiuL, LiuN, ZhaoZ, et al.TNF‐a neutralization improves experimental hepatopulmonary syndrome in rats. Liver Int2012;32:1018. CrossRef

242. SztrymfB, RabillerA, NunesH, et al.Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J2004;23:752. CrossRef

243. KianifarHR, KhalesiM, MahmoodiE, et al.Pentoxifylline in hepatopulmonary syndrome. World J Gastroenterol2012;18:4912. CrossRef

244. GuptaLB. Pentoxifylline therapy for hepatopulmonary syndrome: a pilot study. Arch Intern Med2008;168:1820. CrossRef

245. VaughanRB, AngusPW, Chin‐DustingJP. Evidence for altered vascular responses to exogenous endothelin‐1 in patients with advanced cirrhosis with restoration of the normal vasoconstrictor response following successful liver transplantation. Gut2003;52:1505. CrossRef

246. AsbertM, GinesA, GinesP, et al.Circulating levels of endothelin in cirrhosis. Gastroenterology1993;104:1485.

247. KochDG, BogatkevichG, RamsheshV, et al.Elevated levels of endothelin‐1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans. Dig Dis Sci2011;57:516. CrossRef

248. CarterEP, HartsfieldCL, MiyazonoM, et al.Regulation of heme oxygenase‐1 by nitric oxide during hepatopulmonary syndrome. Am J Physiol Lung Cell Mol Physiol2002;283:L346. CrossRef

249. ArguedasMR, DrakeBB, KapoorA, et al.Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome. Gastroenterology2005;128:328. CrossRef

250. BattagliaSE, PrettoJJ, IrvingLB, et al.Resolution of gas exchange abnormalities and intrapulmonary shunting following liver transplantation. Hepatology1997;25:1228. CrossRef

251. Martinez‐PalliG, GomezFP, BarberaJA, et al.Sustained low diffusing capacity in hepatopulmonary syndrome after liver transplantation. World J Gastroenterol2006;12:5878.

252. SumanovskiLT, BattegayE, StummM, et al.Increased angiogenesis in portal hypertensive rats: role of nitric oxide. Hepatology1999;29:1044. CrossRef

253. ZhangJ, LuoB, TangL, et al.Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology2009;136:1070. CrossRef

254. RobertsKE, KawutSM, KrowkaMJ, et al.Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology2010;139:130. CrossRef

255. FallonMB, AbramsGA. Pulmonary dysfunction in chronic liver disease. Hepatology2000;32:859. CrossRef

256. RobertsDN, ArguedasMR, FallonMB. Cost‐effectiveness of screening for hepatopulmonary syndrome in liver transplant candidates. Liver Transpl2007;13:206. CrossRef

257. AbramsGA, SandersMK, FallonMB. Utility of pulse oximetry in the detection of arterial hypoxemia in liver transplant candidates. Liver Transpl2002;8:391. CrossRef

258. FallonMB, MulliganDC, GishRG, et al.Model for end‐stage liver disease (MELD) exception for hepatopulmonary syndrome. Liver Transpl2006;12(12 Suppl 3):S105. CrossRef

259. GomezFP, Martinez‐PalliG, BarberaJA, et al.Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome. Hepatology2004;40:660. CrossRef

260. McAdamsHP, ErasmusJ, CrockettR, et al.The hepatopulmonary syndrome: radiologic findings in 10 patients. AJR Am J Roentgenol1996;166:1379. CrossRef

261. KoksalD, KacarS, KoksalAS, et al.Evaluation of intrapulmonary vascular dilatations with high‐resolution computed thorax tomography in patients with hepatopulmonary syndrome. J Clin Gastroenterol2006;40:77. CrossRef

262. KrowkaMJ. Hepatopulmonary syndrome: what are we learning from interventional radiology, liver transplantation, and other disorders?Gastroenterology1995;109:1009. CrossRef

263. AllerR, MoyaJL, MoreiraV, et al.Diagnosis and grading of intrapulmonary vascular dilatation in cirrhotic patients with contrast transesophageal echocardiography. J Hepatol1999;31:1044. CrossRef

264. HindCR, WongCM. Detection of pulmonary arteriovenous fistulae in patient with cirrhosis by contrast 2D echocardiography. Gut1981;22:1042. CrossRef

265. ButlerBD, HillsBA. The lung as a filter for microbubbles. J Appl Physiol1979;47:537.

266. FischerCH, CamposO, FernandesWB, et al.Role of contrast‐enhanced transesophageal echocardiography for detection of and scoring intrapulmonary vascular dilatation. Echocardiography2010;27:1233. CrossRef

267. SwansonKL, WiesnerRH, KrowkaMJ. Natural history of hepatopulmonary syndrome: impact of liver transplantation. Hepatology2005;41:1122. CrossRef

268. CorpechotC, BarbuV, WendumD, et al.Hypoxia‐induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology2002;35:1010. CrossRef

269. FukushimaKY, YatsuhashiH, KinoshitaA, et al.Two cases of hepatopulmonary syndrome with improved liver function following long‐term oxygen therapy. J Gastroenterol2007;42:176. CrossRef

270. ShijoH, SasakiH, YuhK, et al.Effects of indomethacin on hepatogenic pulmonary angiodysplasia. Chest1991;99:1027. CrossRef

271. KrowkaMJ, CorteseDA. Severe hypoxemia associated with liver disease: Mayo clinic experience and the experimental use of almitrine bismesylate. Mayo Clin Proc1987;62:164. CrossRef

272. AlmeidaJA, RiordanSM, LiuJ, et al.Deleterious effect of nitric oxide inhibition in chronic hepatopulmonary syndrome. Eur J Gastroenterol Hepatol2007;19:341. CrossRef

273. ZhangJ, LingY, TangL, et al.Pentoxifylline attenuation of experimental hepatopulmonary syndrome. J Appl Physiol2007;102:949. CrossRef

274. TanikellaR, PhilipsGM, FaulkDK, et al.Pilot study of pentoxifylline in hepatopulmonary syndrome. Liver Transpl2008;14:1199. CrossRef

275. CaldwellSH, JeffersLJ, NarulaOS, et al.Ancient remedies revisited: does allium sativum (garlic) palliate the hepatopulmonary syndrome?J Clin Gastroenterol1992;15:248. CrossRef

276. AbramsGA, FallonMB. Treatment of hepatopulmonary syndrome with allium sativum L. (garlic): a pilot trial. J Clin Gastroenterol1998;27:232. CrossRef

277. Najafi SaniM, KianifarHR, KianeeA, et al.Effect of oral garlic on arterial oxygen pressure in children with hepatopulmonary syndrome. World J Gastroenterol2006;12:2427.

278. DeBK, DuttaD, PalSK, et al.The role of garlic in hepatopulmonary syndrome: a randomized controlled trial. Can J Gastroenterol2010;24:183.

279. ChangCC, ChuangCL, LeeFY, et al.Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis. Clin Sci (Lond)2012;124:457. CrossRef

280. Martinez‐PalliG, DrakeBB, Garcia‐PaganJC, et al.Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World J Gastroenterol2005;11:6858. CrossRef

281. KrowkaMJ, PoraykoMK, PlevakDJ, et al.Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Mayo Clin Proc1997;72:44. CrossRef

282. FallonMB. Hepatopulmonary syndrome: more than just a matter of tone?Hepatology2006;43:912. CrossRef

283. ArguedasMR, AbramsGA, KrowkaMJ, et al.Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology2003;37:192. CrossRef

284. IyerVN, SwansonKL, Cartin‐CebaR, et al.Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology2013;57:2427. CrossRef

285. AbramsGA, RoseK, FallonMB, et al.Hepatopulmonary syndrome and venous emboli causing intracerebral hemorrhages after liver transplantation: a case report. Transplantation1999;68:1809. CrossRef

286. Martinez‐PalliG, BarberaJA, TauraP, et al.Severe portopulmonary hypertension after liver transplantation in a patient with preexisting hepatopulmonary syndrome. J Hepatol1999;31:1075. CrossRef

287. MantzFAJr, CraigeE. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. AMA Arch Pathol1951;52:91.

288. SimonneauG, RobbinsIM, BeghettiM, et al.Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol2009;54:S43. CrossRef

289. AbenhaimL, HigenbottamT, RichS. International primary pulmonary hypertension study. Br Heart J1994;71:303. CrossRef

290. KrowkaMJ, PlevakDJ, FindlayJY, et al.Pulmonary hemodynamics and perioperative cardiopulmonary‐related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl2000;6:443. CrossRef

291. RamsayM. Portopulmonary hypertension and right heart failure in patients with cirrhosis. Curr Opin Anaesthesiol2010;23:145. CrossRef

292. SwansonKL, WiesnerRH, NybergSL, et al.Survival in portopulmonary hypertension: Mayo clinic experience categorized by treatment subgroups. Am J Transplant2008;8:2445. CrossRef

293. BudhirajaR, HassounPM. Portopulmonary hypertension: a tale of two circulations. Chest2003;123:562. CrossRef

294. McDonnellPJ, ToyePA, HutchinsGM. Primary pulmonary hypertension and cirrhosis: are they related?Am Rev Respir Dis1983;127:437. CrossRef

295. HadengueA, BenhayounMK, LebrecD, et al.Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology1991;100:520.

296. KrowkaMJ, SwansonKL, FrantzRP, et al.Portopulmonary hypertension: results from a 10‐year screening algorithm. Hepatology2006;44:1502. CrossRef

297. ColleIO, MoreauR, GodinhoE, et al.Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology2003;37:401. CrossRef

298. BenjaminovFS, PrenticeM, SnidermanKW, et al.Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut2003;52:1355. CrossRef

299. KawutSM, KrowkaMJ, TrotterJF, et al.Clinical risk factors for portopulmonary hypertension. Hepatology2008;48:196. CrossRef

300. ChenHS, XingSR, XuWG, et al.Portopulmonary hypertension in cirrhotic patients: prevalence, clinical features and risk factors. Exp Ther Med2013;5:819.

301. RobertsKE. Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Chest2009;135:1470. CrossRef

302. RobertsKE, FallonMB, KrowkaMJ, et al.Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med2009;179:835. CrossRef

303. Porres‐AguilarM, AltamiranoJT, Torre‐DelgadilloA, et al.Portopulmonary hypertension and hepatopulmonary syndrome: a clinician‐oriented overview. Eur Respir Rev2012;21:223. CrossRef

304. HerveP, LebrecD, BrenotF, et al.Pulmonary vascular disorders in portal hypertension. Eur Respir J1998;11:1153. CrossRef

305. McLaughlinVV, McGoonMD. Pulmonary arterial hypertension. Circulation2006;114:1417. CrossRef

306. GolbinJM, KrowkaMJ. Portopulmonary hypertension. Clin Chest Med2007;28:203, ix. CrossRef

307. PellicelliAM, BarbaroG, PuotiC, et al.Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation. Angiology2010;61:802. CrossRef

308. TuderRM, CoolCD, GeraciMW, et al.Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med1999;159:1925. CrossRef

309. KawutSM, TaichmanDB, AhyaVN, et al.Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl2005;11:1107. CrossRef

310. Le PavecJ, SouzaR, HerveP, et al.Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med2008;178:637. CrossRef

311. KrowkaMJ, MillerDP, BarstRJ, et al.Portopulmonary hypertension: a report from the US‐based REVEAL registry. Chest2012;141:906. CrossRef

312. RobalinoBD, MoodieDS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol1991;17:492. CrossRef

313. PilatisND, JacobsLE, RerkpattanapipatP, et al.Clinical predictors of pulmonary hypertension in patients undergoing liver transplant evaluation. Liver Transpl2000;6:85. CrossRef

314. SwansonKL, KrowkaMJ. Arterial oxygenation associated with portopulmonary hypertension. Chest2002;121:1869. CrossRef

315. KuoPC, PlotkinJS, JohnsonLB, et al.Distinctive clinical features of portopulmonary hypertension. Chest1997;112:980. CrossRef

316. MurrayKF, CarithersRLJr, AASLD. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology2005;41:1407. CrossRef

317. Porres‐AguilarM, ZuckermanMJ, Figueroa‐CasasJB, et al.Portopulmonary hypertension: state of the art. Ann Hepatol2008;7:321.

318. YockPG, PoppRL. Noninvasive estimation of right ventricular systolic pressure by doppler ultrasound in patients with tricuspid regurgitation. Circulation1984;70:657. CrossRef

319. CottonCL, GandhiS, VaitkusPT, et al.Role of echocardiography in detecting portopulmonary hypertension in liver transplant candidates. Liver Transpl2002;8:1051. CrossRef

320. KimWR, KrowkaMJ, PlevakDJ, et al.Accuracy of doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl2000;6:453. CrossRef

321. TorregrosaM, GenescaJ, GonzalezA, et al.Role of doppler echocardiography in the assessment of portopulmonary hypertension in liver transplantation candidates. Transplantation2001;71:572. CrossRef

322. RicciGL, MelgosaMT, BurgosF, et al.Assessment of acute pulmonary vascular reactivity in portopulmonary hypertension. Liver Transpl2007;13:1506. CrossRef

323. SwansonKL. What might be learned from acute pulmonary vasodilator testing in portopulmonary hypertension?Liver Transpl2007;13:1498. CrossRef

324. OtaK, ShijoH, KokawaH, et al.Effects of nifedipine on hepatic venous pressure gradient and portal vein blood flow in patients with cirrhosis. J Gastroenterol Hepatol1995;10:198. CrossRef

325. MontaniD, SavaleL, NataliD, et al.Long‐term response to calcium‐channel blockers in non‐idiopathic pulmonary arterial hypertension. Eur Heart J2010;31:1898. CrossRef

326. ProvencherS, HerveP, JaisX, et al.Deleterious effects of beta‐blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology2006;130:120. CrossRef

327. BravermanAC, SteinerMA, PicusD, et al.High‐output congestive heart failure following transjugular intrahepatic portal‐systemic shunting. Chest1995;107:1467. CrossRef

328. MathaiSC, HassounPM. Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin2012;8:413. CrossRef

329. PackerM. Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards. Ann Intern Med1985;103:258. CrossRef

330. KrowkaMJ, FrantzRP, McGoonMD, et al.Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology1999;30:641. CrossRef

331. KuoPC, JohnsonLB, PlotkinJS, et al.Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation1997;63:604. CrossRef

332. McLaughlinVV, GenthnerDE, PanellaMM, et al.Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med1999;130:740. CrossRef

333. SussmanN, KazaV, BarshesN, et al.Successful liver transplantation following medical management of portopulmonary hypertension: a single‐center series. Am J Transplant2006;6:2177. CrossRef

334. AshfaqM, ChinnakotlaS, RogersL, et al.The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant2007;7:1258. CrossRef

335. FixOK, BassNM, De MarcoT, et al.Long‐term follow‐up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl2007;13:875. CrossRef

336. PlotkinJS, KuoPC, RubinLJ, et al.Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation1998;65:457. CrossRef

337. FindlayJY, PlevakDJ, KrowkaMJ, et al.Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg1999;5:362. CrossRef

338. HoeperMM, SeyfarthHJ, HoeffkenG, et al.Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J2007;30:1096. CrossRef

339. MinderS, FischlerM, MuellhauptB, et al.Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J2004;24:703. CrossRef

340. HalankM, MarxC, MiehlkeS, et al.Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension. J Gastroenterol2004;39:1222. CrossRef

341. MelgosaMT, RicciGL, Garcia‐PaganJC, et al.Acute and long‐term effects of inhaled iloprost in portopulmonary hypertension. Liver Transpl2010;16:348.

342. GalieN, OlschewskiH, OudizRJ, et al.Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double‐blind, placebo‐controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation2008;117:3010. CrossRef

343. RubinLJ, BadeschDB, BarstRJ, et al.Bosentan therapy for pulmonary arterial hypertension. N Engl J Med2002;346:896. CrossRef

344. HalankM, MiehlkeS, HoeffkenG, et al.Use of oral endothelin‐receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation2004;77:1775. CrossRef

345. HinterhuberL, GraziadeiIW, KahlerCM, et al.Endothelin‐receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol2004;2:1039. CrossRef

346. StahlerG, von HunniusP. Successful treatment of portopulmonary hypertension with bosentan: case report. Eur J Clin Invest2006;36(Suppl 3):62. CrossRef

347. HoeperMM, HalankM, MarxC, et al.Bosentan therapy for portopulmonary hypertension. Eur Respir J2005;25:502. CrossRef

348. KuntzenC, GulbergV, GerbesAL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?Gastroenterology2005;128:164. CrossRef

349. BarthF, GerberPJ, ReichenJ, et al.Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency. Eur J Gastroenterol Hepatol2006;18:1117. CrossRef

350. SavaleL, MagnierR, Le PavecJ, et al.Efficacy, safety, and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J2013;41:96. CrossRef

351. Cartin‐CebaR, SwansonK, IyerV, et al.Safety and efficacy of ambrisentan for the therapy of portopulmonary hypertension. Chest2011;139:109. CrossRef

352. GalieN, GhofraniHA, TorbickiA, et al.Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med2005;353:2148. CrossRef

353. OudizRJ, BrundageBH, GalieN, et al.Tadalafil for the treatment of pulmonary arterial hypertension: a double‐blind 52‐week uncontrolled extension study. J Am Coll Cardiol2012;60:768. CrossRef

354. Callejas RubioJL, Salmeron EscobarJ, Gonzalez‐CalvinJ, et al.Successful treatment of severe portopulmonary hypertension in a patient with child C cirrhosis by sildenafil. Liver Transpl2006;12:690. CrossRef

355. ChuaR, KeoghA, MiyashitaM. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant2005;24:498. CrossRef

356. MakisaloH, KoivusaloA, VakkuriA, et al.Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl2004;10:945. CrossRef

357. ReichenbergerF, VoswinckelR, StevelingE, et al.Sildenafil treatment for portopulmonary hypertension. Eur Respir J2006;28:563. CrossRef

358. GoughMS, WhiteRJ. Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transpl2009;15:30. CrossRef

359. HemnesAR, RobbinsIM. Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transpl2009;15:15. CrossRef

360. TzathasC, ChristidouA, LadasSD. Sildenafil (viagra) is a risk factor for acute variceal bleeding. Am J Gastroenterol2002;97:1856. CrossRef

361. FinleyDS, LugoB, RidgwayJ, et al.Fatal variceal rupture after sildenafil use: report of a case. Curr Surg2005;62:55. CrossRef

362. RibasJ, AngrillJ, BarberaJA, et al.Isosorbide‐5‐mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. Eur Respir J1999;13:210. CrossRef

363. FindlayJY, HarrisonBA, PlevakDJ, et al.Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Liver Transpl Surg1999;5:381. CrossRef

364. FukazawaK, PoliacLC, PrettoEA. Rapid assessment and safe management of severe pulmonary hypertension with milrinone during orthotopic liver transplantation. Clin Transplant2010;24:515. CrossRef

365. KrowkaMJ, MandellMS, RamsayMA, et al.Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl2004;10:174. CrossRef

366. KoneruB, FisherA, WilsonDJ, et al.De novo diagnosis of portopulmonary hypertension following liver transplantation. Am J Transplant2002;2:883. CrossRef

367. KettDH, AcostaRC, CamposMA, et al.Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation. Liver Transpl2001;7:645. CrossRef

368. YoshidaEM, ErbSR, PflugfelderPW, et al.Single‐lung versus liver transplantation for the treatment of portopulmonary hypertension–a comparison of two patients. Transplantation1993;55:688.

369. KrowkaMJ, WiesnerRH, HeimbachJK. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward. J Hepatol2013;59:367. CrossRef

370. HollatzTJ, MusatA, WestphalS, et al.Treatment with sildenafil and treprostinil allows successful liver transplantation of patients with moderate to severe portopulmonary hypertension. Liver Transpl2012;18:686. CrossRef

371. KrowkaMJ, FallonMB, MulliganDC, et al.Model for end‐stage liver disease (MELD) exception for portopulmonary hypertension. Liver Transpl2006;12(12 Suppl 3):S114. CrossRef

372. CseteM. Intraoperative management of liver transplant patients with pulmonary hypertension. Liver Transpl Surg1997;3:454. CrossRef

373. KrowkaMJ. Evolving dilemmas and management of portopulmonary hypertension. Semin Liver Dis2006;26:265. CrossRef

374. LevyMT, TorzilloP, BookallilM, et al.Case report: delayed resolution of severe pulmonary hypertension after isolated liver transplantation in a patient with cirrhosis. J Gastroenterol Hepatol1996;11:734. CrossRef

375. TeasdalG, JennetB. Glasgow coma scale. Lancet1974;304:81. CrossRef